Abstract Background: The prevalence of the @entity209 ( @entity209 ) increases after the menopause. Reports indicate that the @entity209 and its components, especially @entity28 , enhance the intensity of menopausal symptoms. Objective: Assess the frequency and severity of menopausal symptoms in postmenopausal @entity1 . Factors related to the symptom severity were also analyzed including @entity308 and metabolic status. Methods: A total of 204 natural postmenopausal @entity1 (40-65 years) participating in a @entity209 screening program were asked to fill out the @entity1168 ( @entity1168 ), the Hospital Anxiety and @entity308 Scale (HADS), and a general socio-demographic questionnaire containing personal and partner data. Criteria of the American Heart Association were used to define the @entity209 . Results: Median age of the whole sample was 56 years. A 52.9% presented the @entity209 , with 37.3% presenting @entity4854 , 51.5% @entity101 , 58.3% @entity1144 , 45.6% high @entity412 and 56.4% low HDL-C levels. Total and subscale @entity1168 scores did not differ in accordance to the presence or not of the @entity209 . The three top prevalent menopausal symptoms were muscle and joint problems (87.2%), physical and mental exhaustion (72%) and @entity308 mood (64.7%). A 19.6% of @entity1 presented @entity1168 above 16 defined as severe. Multivariate linear regression analysis determined that @entity148 (higher HADS @entity148 subscale scores) was significantly and positively correlated with all components of the @entity1168 (Total and subscale scores). Higher @entity1168 correlated positively with abdominal perimeter and higher parity. Somatic scores correlated inversely with female education and positively with psychotropic drug use; and psychological @entity1168 scores positively correlated depressed mood (higher HADS @entity308 subscale scores) and abdominal perimeter. Conclusion: In this postmenopausal sample, severity of menopausal symptoms correlated to @entity1144 , mood and other personal aspects.

Evaluation of the presence and severity of menopausal symptoms among postmenopausal XXXX screened for the @entity209 .

@entity1 :: ('9606', 'Species') :: ['women'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressive'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity1144 :: ('MESH:D056128', 'Disease') :: ['abdominal obesity'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity209 :: ('MESH:D008659', 'Disease') :: ['METS', 'metabolic syndrome'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['total MRS scores', 'MRS', 'Menopause Rating Scale'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']
@entity1 :: (9606,Species) :: ['women']
